We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer

This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier:
First Posted: October 10, 2012
Last Update Posted: June 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Prostate Cancer Foundation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Washington
This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition Intervention
Adenocarcinoma of the Prostate Castration-resistant Prostate Cancer Recurrent Prostate Cancer Stage III Prostate Cancer Stage IV Prostate Cancer Drug: cabozantinib-s-malate Other: laboratory biomarker analysis

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

Resource links provided by NLM:

Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Change in urinary N-telopeptide (uNTX) [ Time Frame: Baseline and 6 weeks ]
    Will be analyzed after log-transformation.

Secondary Outcome Measures:
  • Toxicity assessed using CTCAE version 4.0 [ Time Frame: Up to 4 weeks post-treatment ]
    Toxicity will be described by grade and frequency.

  • Progression-free survival [ Time Frame: Up to 4 weeks post-treatment ]
    Kaplan-Meier methods will be used to report progression-free survival.

  • Time to progression [ Time Frame: From date of registration to date of progressive disease, assessed up to 4 weeks post-treatment ]
    Kaplan-Meier methods will be used to report time to progression.

  • Objective response [ Time Frame: Up to 4 weeks post-treatment ]
    Proportions and 95% binomial confidence intervals will be reported for objective response.

  • PSA response [ Time Frame: Up to 4 weeks post-treatment ]
    Proportions and 95% binomial confidence intervals will be reported for PSA response.

  • Duration of response [ Time Frame: Up to 4 weeks post-treatment ]
    Mean and the corresponding standard deviation will be used to describe the duration of response among responders.

  • Changes in dynamic histomorphometry of involved and uninvolved bone [ Time Frame: Baseline and 6 weeks ]
    Logistic models will be used.

  • Changes in bone and serum markers of bone metabolism [ Time Frame: Baseline, 6 weeks and 12 weeks ]
    Will be explored using a linear mixed model to determine if there is a difference in these markers over time between patients with progressive disease and those without.

Enrollment: 9
Actual Study Start Date: June 18, 2013
Estimated Study Completion Date: April 1, 2019
Estimated Primary Completion Date: February 18, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (cabozantinib)
Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
Drug: cabozantinib-s-malate
Given PO
Other Names:
  • BMS-907351
  • Cometriq
  • XL184
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. To assess the impact of cabozantinib on markers of bone turnover and microenvironment in men with non-metastatic castration-resistant prostate cancer and to compare the findings in men with metastatic castration-resistant prostate cancer.


I. To describe the associated changes in dynamic histomorphometry at baseline and after 6 weeks of cabozantinib therapy in men with non-metastatic castration-resistant prostate cancer.

II. To characterize, describe, and compare the effects of cabozantinib in men with non-metastatic and metastatic bone disease with respect to the following measurements at baseline and on therapy: markers of bone metabolism in blood including bone specific alkaline phosphatase, alkaline phosphatase, lactate dehydrogenase (LDH); changes in markers of apoptosis, proliferation, and angiogenesis in biopsy specimens from both bone and soft tissue during therapy with cabozantinib.


I. Radiographic disease responses and toxicities will be monitored for all patients.


Patients receive cabozantinib orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Key Inclusion Criteria

  • The subject has a proven histologic diagnosis of prostate adenocarcinoma, but may have undergone prior surgery and/or radiation
  • The subject must currently have castration resistant prostate cancer defined as 2 serial rising prostate-specific antigens (PSAs) with a castrate level of testosterone (< 50 ng/dL)
  • A subject with non-metastatic castration-resistant prostate cancer (CRPC) may not have received prior chemotherapy unless in the neoadjuvant or adjuvant setting > 24 months ago and may not have received prior zoledronic acid or denosumab
  • A subject with metastatic CRPC must have bone metastases accessible for biopsy by computed tomography (CT) guidance
  • The subject must be willing to undergo sequential biopsy of bone or bone metastases
  • Adequate organ and bone marrow function.
  • The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document

Key Exclusion Criteria

  • Prior treatment with cabozantinib and other met inhibitors
  • Cytotoxic chemotherapy or biologic agents within 3 weeks of study treatment
  • Recent radiation therapy (3 months for thoracic cavity, 14 days for bone or brain metastasis, 28 days for other sites) or radionuclide treatment within 6 weeks of starting study drug.
  • The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
  • The subject has not recovered from toxicities due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
  • The subject has primary brain tumor or active brain metastases or epidural
  • Coagulation tests need to be adequate for the study
  • The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (eg, clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted
  • The subject requires chronic concomitant treatment of strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's Wort)
  • History of clinically significant gastrointestinal bleeding
  • The subject has uncontrolled, significant intercurrent or recent illness
  • The subject is unable to swallow tablets
  • The subject has a corrected QT interval (QTcF) > 500 ms within 28 days before day 1 of cycle 1
  • The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation or to tetracycline
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01703065

United States, Washington
Seattle Cancer Care Alliance/University of Washington
Seattle, Washington, United States, 98109
Sponsors and Collaborators
University of Washington
Prostate Cancer Foundation
National Cancer Institute (NCI)
Principal Investigator: Celestia Higano Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
  More Information

Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT01703065     History of Changes
Other Study ID Numbers: 7819
NCI-2012-01898 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
P30CA015704 ( U.S. NIH Grant/Contract )
First Submitted: October 5, 2012
First Posted: October 10, 2012
Last Update Posted: June 16, 2017
Last Verified: June 2017

Keywords provided by University of Washington:
Prostate cancer
Bone metastases

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type